Skip to main content
KyungdongPharm logo

KyungdongPharm — Investor Relations & Filings

Ticker · 011040 ISIN · KR7011040003 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2021-02-19 Major Shareholding Noti…
Country KR South Korea
Listing KO 011040

About KyungdongPharm

https://kdpharma.co.kr

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Recent filings

Filing Released Lang Actions
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a regulatory filing in South Korea required when a person or entity acquires or changes a significant stake (typically 5% or more) in a company. The document explicitly details changes in shareholding percentages, lists special related parties, and provides a breakdown of transactions (buy/sell). This falls under the 'Major Shareholding Notification' category.
2021-02-19 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Stock Collateral Agreement' (주식 담보제공 계약) involving a major shareholder. This type of disclosure relates to changes in capital structure and share ownership status due to collateralization. Since it does not fit into specific categories like 'Director's Dealing' (which usually refers to personal trades) or 'Share Issue' (which refers to new issuance), and it is a standard regulatory disclosure for Korean listed companies, it is classified as a Regulatory Filing (RNS).
2021-02-17 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식처분결과보고서' (Report on the Results of Disposal of Treasury Shares) filed with the Financial Supervisory Service (FSS) of South Korea. It details the specific quantity, price, and purpose (employee bonus) of treasury shares disposed of by the company. This falls under the category of a company reporting its own share transactions, which corresponds to the 'Transaction in Own Shares' (POS) category.
2021-02-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Kyungdong Pharmaceutical) regarding a significant change in financial structure (revenue/profit fluctuation). This is a standard disclosure required by the Korea Exchange (KRX) when financial results deviate by more than 15-30% from the previous year. Since it is a specific regulatory disclosure of financial performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Regulatory Filings' category. FY 2020
2021-02-10 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Kyungdong Pharmaceutical regarding a decision on cash dividends. It specifies the dividend amount per share, the record date, the payment date, and the approval process by the board of directors. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2021-02-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Kyungdong Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, dividend declaration, and director appointments) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of the meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2021-02-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.